129 related articles for article (PubMed ID: 8305389)
1. Intervention debulking surgery in advanced epithelial ovarian cancer.
Redman CW; Warwick J; Luesley DM; Varma R; Lawton FG; Blackledge GR
Br J Obstet Gynaecol; 1994 Feb; 101(2):142-6. PubMed ID: 8305389
[TBL] [Abstract][Full Text] [Related]
2. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
3. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
4. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.
Rosen B; Laframboise S; Ferguson S; Dodge J; Bernardini M; Murphy J; Segev Y; Sun P; Narod SA
Gynecol Oncol; 2014 Sep; 134(3):462-7. PubMed ID: 25026637
[TBL] [Abstract][Full Text] [Related]
5. Interval debulking surgery for advanced epithelial ovarian cancer.
Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P
Cochrane Database Syst Rev; 2008 Oct; (4):CD006014. PubMed ID: 18843699
[TBL] [Abstract][Full Text] [Related]
6. [Early debulking surgery after chemotherapy in advanced cancer of the ovary].
de Gramont A; Pigné A; Louvet C; Sezeur A; Marpeau L; Vaillant JC; Cady J; Varette C; Demuynck B; Couturier JY; Lagadec B; Milliez J; Barrat J; Krulik M
Ann Chir; 1997; 51(10):1069-76. PubMed ID: 10868028
[TBL] [Abstract][Full Text] [Related]
7. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
8. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
Vergote I; De Wever I; Tjalma W; Van Gramberen M; Decloedt J; van Dam P
Gynecol Oncol; 1998 Dec; 71(3):431-6. PubMed ID: 9887245
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.
May T; Comeau R; Sun P; Kotsopoulos J; Narod SA; Rosen B; Ghatage P
Int J Gynecol Cancer; 2017 May; 27(4):668-674. PubMed ID: 28441250
[TBL] [Abstract][Full Text] [Related]
11. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
12. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer.
Lawton FG; Redman CW; Luesley DM; Chan KK; Blackledge G
Obstet Gynecol; 1989 Jan; 73(1):61-5. PubMed ID: 2462202
[TBL] [Abstract][Full Text] [Related]
14. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.
van der Burg ME; van Lent M; Buyse M; Kobierska A; Colombo N; Favalli G; Lacave AJ; Nardi M; Renard J; Pecorelli S
N Engl J Med; 1995 Mar; 332(10):629-34. PubMed ID: 7845426
[TBL] [Abstract][Full Text] [Related]
15. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
16. Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer.
Grabowski JP; Harter P; Hils R; Lorenz D; Kaub C; Barinoff J; Heitz F; Traut A; du Bois A
Gynecol Oncol; 2012 Jul; 126(1):54-7. PubMed ID: 22472462
[TBL] [Abstract][Full Text] [Related]
17. The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.
Tsolakidis D; Amant F; Van Gorp T; Leunen K; Neven P; Vergote I
Int J Gynecol Cancer; 2010 May; 20(4):542-51. PubMed ID: 20686373
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
19. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
20. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
